PRESS RELEASE published on 12/03/2024 at 14:29, 1 year 5 months ago Eckert & Ziegler: Changes in the Executive Board and Supervisory Board Eckert & Ziegler SE appoints Dr. Gunnar Mann to Executive Board and welcomes changes in Supervisory Board. Dr. Mann to lead Medical segment Executive Board Supervisory Board Eckert & Ziegler SE Medical Segment Dr. Gunnar Mann
BRIEF published on 12/02/2024 at 09:05, 1 year 5 months ago Eckert & Ziegler Initiates Actinium-225 Production to Tackle Global Shortage Nuclear Medicine Radiopharmaceuticals Actinium-225 Production Isotope Supply GMP Certification
PRESS RELEASE published on 12/02/2024 at 09:00, 1 year 5 months ago Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply Eckert & Ziegler starts Actinium-225 production in collaboration with Czech Academy of Sciences, aiming for GMP-grade supply to boost alpha-emitting radiopharmaceuticals development Eckert & Ziegler Production Radiopharmaceuticals Actinium-225 GMP-grade
BRIEF published on 11/27/2024 at 09:05, 1 year 6 months ago Eckert & Ziegler Gains European Approval for Theralugand® Cancer Therapy Radiopharmaceuticals Lutetium-177 European Approval Theralugand®
PRESS RELEASE published on 11/27/2024 at 09:00, 1 year 6 months ago Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a) Eckert & Ziegler receives EC approval for Theralugand® - Lutetium-177 Chloride, expanding cancer therapy options in Europe Eckert & Ziegler Cancer Therapy EC Approval Theralugand Lutetium-177 Chloride
BRIEF published on 11/22/2024 at 15:32, 1 year 6 months ago Eckert & Ziegler Increases 2024 Financial Forecast Eckert & Ziegler Sales Increase Financial Forecast EBIT Growth 2024 Business
PRESS RELEASE published on 11/22/2024 at 15:27, 1 year 6 months ago EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again Eckert & Ziegler SE raises its forecast for the current financial year with sales of EUR 290 million and EBIT of EUR 60 million. Investor contact: Karolin Riehle, EZAG Financial Year Forecast Eckert & Ziegler SE EUR 290 Million EBIT EUR 60 Million
BRIEF published on 11/14/2024 at 07:50, 1 year 6 months ago Eckert & Ziegler Reports Strong Growth in First Nine Months of 2024 Eckert & Ziegler 2024 Forecast Financial Growth Medical Segment Isotope Products
PRESS RELEASE published on 11/14/2024 at 07:45, 1 year 6 months ago Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024 Eckert & Ziegler SE reports strong 9-month results with 17% sales growth reaching €215.5 million. Forecasting €55 million EBIT for 2024. Explore more at: https://www.ezag.com/q32024en/ Sales Growth EBIT 2024 Forecast Eckert & Ziegler SE 9-Month Results
BRIEF published on 11/13/2024 at 08:59, 1 year 6 months ago Eckert & Ziegler Forge Alliance with Telix Pharmaceuticals for Actinium-225 Clinical Trials Eckert & Ziegler Telix Pharmaceuticals Radiopharmaceuticals Actinium-225
Published on 05/27/2026 at 15:25, 4 hours 14 minutes ago LaFleur Announces Upsize of Bought Deal Equity Offerings for Gross Proceeds of C$10 Million
Published on 05/27/2026 at 15:22, 4 hours 17 minutes ago AmeriTrust Announces First Quarter 2026 Financial Results
Published on 05/27/2026 at 15:15, 4 hours 24 minutes ago Storm Exploration Begins Field Program on VMS Target at Gold Standard
Published on 05/27/2026 at 15:00, 4 hours 39 minutes ago Jaguar Health Compliant with Nasdaq Bid Price Rule
Published on 05/27/2026 at 14:49, 4 hours 50 minutes ago Sekur Private Data Signs Defense Distribution Agreement with Elyon International, Marking Strategic Shift to Defense, Government and Enterprise Communications
Published on 05/27/2026 at 19:10, 29 minutes ago 124th Annual General Meeting of Romande Energie Holding SA
Published on 05/27/2026 at 18:30, 1 hour 9 minutes ago Avolta secures 12-year contract at Norfolk International Airport, introducing hybrid formats
Published on 05/27/2026 at 18:13, 1 hour 26 minutes ago Energiekontor AG: Annual General Meeting approves all agenda items by a large majority
Published on 05/27/2026 at 17:45, 1 hour 54 minutes ago Imerys-05-2026-information-share-capital-and-voting-rights-as-of-30-April-2026
Published on 05/27/2026 at 17:45, 1 hour 54 minutes ago Description of Share buyback program - May 2026
Published on 05/27/2026 at 17:45, 1 hour 54 minutes ago Report on share repurchases from 20 to 26 May 2026
Published on 05/27/2026 at 17:45, 1 hour 54 minutes ago Report ordinary & special general meeting of May 27, 2026
Published on 05/27/2026 at 11:51, 7 hours 48 minutes ago Statement of transactions in own shares from May 18, 2026 to May 22, 2026
